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AN enteritis, based on a delayed-type hypersensitivity
reaction, was induced in TNBS (2,4,4-trinitrobenzene-
sulphonic acid) sensitized rats by multiple intrajejunal
challenge with TNBS via an implanted catheter. This
treatment induced chronic inflammation of the distal small
intestine characterized by intense hyperaemia, oedema
and gut wall thickening as assessed by macroscopic
scoring and weighing a defined part of the dissected
intestine. Histologically, the inflammatory response
included mucosal and submucosal cell infiltration by
lymphocytes and histiocytes, transmural granulomatous
inflammation with multinucleated cells and activated
mesenteric lymph nodes. Ex vivo stimulated release of the
inflammatory mediator LTB in the dissected part of the
intestine was increased following TNBS treatment. Drug
treatment with sulphasalazine or 5-aminosalicylic acid
improved the enteritis score and attenuated TNBS-
induced oedema formation and LTB4 production. The
applicability and relevance of this new model are
discussed with respect to drug development and basic
research of inflammatory bowel diseases.
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Introduction
Inflammatory bowel diseases, Crohn’s disease
(CD) and ulcerative colitis (UC), represent chronic
inflammation of the gastrointestinal tract of
unknown aetiology involving immunological
events. Recently, these immunological parameters
have been described as secondary but may possibly
be attributed to the chronicity of the disease.
>3
Research on the aetiopathogenesis of inflammatory
bowel disease and testing of potential therapeutic
agents has been hampered by the paucity of
reproducible and histopathologically relevant ani-
mal models of chronic intestinal inflammation.
Recently, colitis was induced in rats by a single
local application of TNBS dissolved in ethanol as
a mucosal irritant.4 This procedure induced a
severe and prolonged degenerative inflammation
of large parts of the colon. This model shared
several aspects of the human inflammatory bowel
disease (IBD); and a chronic bowel inflammation,
with the typical histopathological infiltration of
lymphocytes and histiocytes including granuloma
formation and Langhans-type giant cells, was
observed. The induction of the disease by a single
Part of this study has been presented at the ’13th European Workshop
on Inflammation’, May 1991, and will be published as an
extended abstract in Agents and Actions in 1992.
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destructive event is quite different to a more or
less continuous or weak stimulation of the
immune system by one or more immunogens that
might be one of the multiple factors causing
human IBDs. We intended to mimic the human
disease more closely by realizing the following
three-step concept, using TNBS (2,4,4-trinitro-
benzenesulphonic acid) as a defined hapten:
1. specific hypersensitivity by active immuniza-
tion
2. local inflammation by local challenge
3. chronicity by chronic application of the
immunogen.
Materials and Methods
Immunization: Female Sprague-Dawley rats (150-
200 g) were sensitized by intradermal injection of
0.8% TNBS (Fluka, Neu-Ulm, Germany), into a
shaved area on the back once daily for 3 consecutive
days. TNBS was dissolved in 0.05 ml Freund’s
incomplete adjuvant (FIA; Difco, Detroit, Michi-
gan, USA) together with 1 mg/ml ovalbumin (OA;
Sigma, Deisenhofen, Germany). After 18 days the
animals received a further intradermal booster
injection. Intradermal challenge of 0.08% TNBS in
0.05 ml 0.9% NaC1 solution with or without OA,
or OA solution without TNBS, was given 14 days
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later in order to determine the type and specificity
of the immunological reaction.
Induction of enteritis: Ten days after the intradermal
challenge a flexible polyethylene tube of 0.5 mm
diameter was implanted under ketamine anaesthesia
(100 mg/kg i.p.) 15 cm proximal to the caecum and
emerging at the neck for TNBS or drug
administration. After a 10-day recovery phase the
animals, kept in separate cages, were treated daily
for 3 weeks with 0.08% TNBS in saline (0.2 mg/rat)
given intraluminally, control groups receiving only
saline. Rats were killed by CO2 asphyxiation 24 h
after the last intraluminal application of TNBS. The
distal 10cm of small intestine anterior to the
ileocaecocolic junction (5 cm distance to the open
end of the catheter) including Peyer’s patches were
dissected, cut open longitudinally and rinsed with
saline (15C).
Assessment of enteritis: Immediately after dissection,
the distal small intestine was visually assessed for
inflammation by two independent observers accord-
ing to the enteritis score outlined in Table 1. This
.scoring system includes the intensity and extent of
the redness, or hyperaemia, one of the main
parameters of inflammation, where 0 is defined as
no visible damage of the whole 10 cm of the distal
small intestine, 0.5 slight redness of less than 50%
of the whole 10 cm, 1.0--slight redness of the
whole 10 cm, 1.5 intense redness of about 25%
of the 10 cm, 2.0 intense redness of about 50%
of the whole 10 cm, 2.5 intense redness of about
75% of the whole 10 cm and 3.0 intense redness
of the whole 10 cm. The dissected gut segments,
precisely 10 cm long, were weighed as a parameter
of oedema formation and then incubated in 1 ml
Tris buffer (50 mM, pH 7.4, 100 mm NaC1, 1 mm
Gag12, 1 mg/ml glucose)/100 mg tissue for 30 min-
utes at 37C in a shaking water bath. Following
incubation, aliquots of the solutions were cen-
trifuged (13000g, 2min, 20C) and the super-
natants stored (-28C) for determination of
Table 1. Criteria and score for gross morphological damage
Enteritis score Gross morphology
0 No damage
Slight inflammation
Slight hyperaemia
Visible villi*
Intermediate inflammation
Discontinuous hyperaemia
Intermediate redness of villi*
Intense inflammation
Intense hyperaemia
Intense redness of villi,
’Tile structure’ of villi*
Observed under x 15 magnification.
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leukotriene B4 (LTB4) by radioimmunoassay.
Supernatants were used without prior extraction or
chromatography and measured by specific radio-
immunoassays for LTB4 purchased from Amer-
sham Buchler, Brunswick, Germany.
Histology: To confirm the visual assessment of
inflammation, segments of inflamed and unaffected
distal small intestine, obtained from the same
animal, were fixed in 10% neutral buffered formalin
and processed routinely before embedding in
paraffin. The paraffin sections were stained with
haematoxylin and eosin and examined by light
microscopy.
Statistical analysis" Results were expressed as mean
-F SEM of (n) experiments. Differences between
control and inflamed tissue, and influence of drug
treatment were compared within each experiment,
and statistical significance was calculated by
Wilcoxon-Mann-Whitney U-test for unpaired data,
two-tailed, the level of significance being taken as
p _< 0.05.
Drug treatment: Drugs were applied either orally
(p.o.) by gavage twice a day, suspended in 1,%
carboxymethylcellulose (CMC), or intraluminally
(i.1.) once a day, suspended in saline. The intervals
between oral drug applications were 10--14 h per
day, the intervals between intraluminal drug
applications were 24h per day. The intervals
between drug and TNBS application were 5 h for
oral drug application, and 12 h for intraluminal
application. Drugs used were 5-aminosalicylic acid
(5-ASA; Heraeus, Karlsruhe, Germany) 21.5
mg/kg/day i.1. or 2 x 21.5 mg/kg/day orally and
sulphasalazine (SAZ; Pharmacia) 46.4 mg/kg/day
i.1. or 2 x 46.4 mg/kg/day orally. Control groups
received only CMC or saline.
Results
Compared to untreated non-operated animals
implantation of a tube did not affect weight gain
and well-being of groups of sham-operated animals
and groups of animals which additionally received
multiple intraluminal application of saline or CMC.
In addition, no visible redness or haemorrhage or
oedema formation, or any histological difference
compared to untreated animals, was detectable
except for local granuloma formation just around
the fixation points of the tube.
In preliminary experiments a 0.08% solution of
TNBS (0.20mg/rat) was found to cause a
reproducible slight inflammation 24 h after a single
local administration in sensitized animals, but not
in non-sensitized rats. At a lower TNBS concentra-
tion (0.01%; 0.025 mg/rat) the inflammation was
not reproducible, whereas 0.5% (1.25mg/rat)TNBS-induced enteritis in rats
TNBS had a direct inflammatory action on the gut
of non-TNBS-sensitized rats.
Investigations on days 7, 14, 21 and 28 of TNBS
application were carried out in order to determine
the minimum time taken to reach a chronic stage
of intestinal inflammation. Only 3 and 4 weeks of
application ofTNBS resulted in a reproducible state
of the inflammatory reaction in each animal.
Therefore a 21-day challenge was chosen for the
following investigations.
The immunization procedure induced a re-
producible and prolonged (9 months) delayed type
hyperreactivity against TNBS, and TNBS bound to
OA, but not against OA itself. This was examined
by repeated monthly intradermal injections of
non-irritating doses of TNBS alone or TNBS
bound to OA, or OA alone.
Chronic TNBS-induced inflammation of the
distal small intestine in rats was characterized by
intense hyperaemia and oedema of the mucosal
surface 5-15 cm distal to the end of the implanted
catheter. Histological examination of this part of
the intestine showed inflammatory cell infiltration
mainly by lymphocytes and histiocytes in all layers
of the intestinal wall. No infiltration of neutrophils
was seen in any of the sections obtained, and goblet
cells were always intact (Figs 1 and 2). Transmural
granulomatous inflammation of the gut wall, with
multinucleated cells and activated Peyer’s patches,
was also observed microscopically (Figs 3 and 4).
No differences compared to untreated animals were
seen in proximal small intestines or colons from
TNBS-treated rats.
Intraluminal TNBS treatment induced moderate
to intense inflammation of the distal small intestine
as examined according to the scoring system
described in Table 1 (see Materials and Methods).
Mean values obtained from ten animals per group
were 2.35 0.15 and 2.0 -F 0.08, after TNBS with
orally or intraluminally administered drug-Vehicle,
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FIG. 1. Histologic section of distal small intestine (ileum) from a control
rat. Tissue sample was taken and fixed immediately after sacrifice. Note
the intact mucosal cylinder-shaped villi and crypts (epithelial layer).
There is also no histologically detectable damage in the submucosa and
muscular coat; 80.
FIG. 2. Paraffin section of ileum after TNBS sensitization and
TNBS treatment showing moderate focal mononuclear cell infiltration in
the lamina propria and submucosa. Note the tissue disorganization in the
area of the inflammatory process. Tissue sample was taken and fixed
immediately after sacrifice; x 80.
FIG. 3. Section of ileum after TNBS sensitization and TNBS treatment
including activated gut-associated lymphoid tissue (Peyer’s patch, left
upper part of the figure). Note the severe mucosal lymphohistiocytic
infiltration and incipient fibroblastic proliferation in the epithelial layer
and lamina propria extending through the lamina muscularis mucosae.
The area of chronic inflammatory response is lined with intact glandular
mucosa. Ileum sample was taken and fixed immediately after sacrifice;
x 80.
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FIG. 4. Granulomatous reaction in the ileum of a TNBS-sensitized and
TNBS-treated rat. Ileum sample was taken and fixed immediately after
sacrifice. The submucosal granuloma is characterized by compact, sharply
outlined aggregates of epithelioid histiocytes and numerous multi-
nucleated Langhans-type giant cells accompanied by lymphocytes of
fibroblastic proliferation; x 200.
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respectively; and 2.19 _+ 0.16 after TNBS without
further drug-vehicle administration (Fig. 5). Ulcera-
tions were not observed in any of the animals
treated with 0.08% TNBS.
Local saline instead of TNBS treatment induced
no or only slight inflammation in some animals
which was also observed in naive animals, see Fig.
5. In non-TNBS-sensitized animals intraluminal
TNBS (0.08%) did not induce intense hyperaemia,
although some animals showed slight hyperaemia
but without any histological signs of inflammation.
Chronic TNBS treatment in sensitized animals
induced a significant increase in gut weight, which
was used as an unspecific parameter of oedema
formation or development of granulomatous
inflammation. TNBS increased the normal weight
of a constant 10 cm of gut from about 730 mg to
about 1100 mg (Fig. 6). In sensitized rats chronic
TNBS treatment also significantly increased LTB4
production of incubated gut sections in comparison
to saline-treated groups, 255 __+ 51.8 pg/g tissue
(TNBS) vs 14 -t- 2.6 pg/g tissue (NaC1) (Fig. 7).
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FIG. 5. Effect of (A) orally (p.o.) and (B) intraluminally (i.I.) supplied
sulphasalazine (SAZ) and 5-aminosalicylic acid (5-ASA) on the enteritis
score in TNBS-induced inflammation of distal small intestine. SAZ was
used in doses of 2 x 46.4 mg/kg/day p.o. (A) and 46.4 mg/kg/day i.l.
(B). 5-ASA was used in doses of 2 x 21.5 mg/kg/day p.o. (A) and
21.5 mg/kg/day i.I. (B). Each bar represents the mean (-I-SEM) of ten
rats/group. p _< 0.05 vs. vehicle-treated TN BS-sensitized animals.
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FIG. 6. Effect of (A) orally (p.o.) and (B) intraluminally (i.I.) applied
sulphasalazine (SAZ) and 5-aminosalicylic acid (5-ASA) on gut weight
in TNBS-induced inflammation of distal small intestine. SAZ was used
in doses of 2 x 46.4 mg/kg/day p.o. (A) and 46.4 mg/kg/day i.l. (B).
5-ASA was used in doses of 2 x 21.5mg/kg/day p.o. (A) and
21.5 mg/kg/day i.I. (B). Each bar represents the mean (+_SEM) of ten
rats/group. p _< 0.05 vs. vehicle-treated TNBS-sensitized animals.
Oral or intraluminal treatment with sulphasala-
zine (SAZ) and 5-aminosalicylic acid (5-ASA),
administered in doses of 2 x 46.4 or 46.4
mg/kg/day (i.1.), or 2 x 21.5 mg/kg/day (p.o.) or
21.5 mg/kg/day (i.1.), improved all parameters used
in this model. Enteritis score was decreased from
2.19 to 1.3 or 1.04 by oral treatment, and from 2.0
to 0.9 or 0.85 by intraluminal treatment with SAZ
or 5-ASA (Fig. 5). Intraluminal administration of
half the oral dose seemed to induce an equipotent
anti-inflammatory effect on the enteritis score. The
TNBS-induced increase in gut weight was reduced
by oral and intraluminal treatment with SAZ and
5-ASA to such an extent that there was no
detectable difference between these and sham-
operated, saline-treated, TNBS-sensitized animals
(Fig. 6). LTB4 production by incubated gut sections
from treated animals was reduced more markedly
by oral than by intraluminal SAZ or 5-ASA
treatment (Fig. 7A). Oral treatment (Fig. 7) induced
a 90% or 85% reduction as compared to TNBS
control values, whereas intraluminal treatment only
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FIG. 7. Effect of (A) orally (p.o.) and (B) intraluminally (i.I.) applied
sulphasalazine(SAZ) and 5-aminosalicylic acid (5-ASA) on ex vivo
leukotriene B4 production of TNBS-treated distal small intestine. SAZ
was used in doses of 2 x 46.4 mg/kg/day p.o. (A) and 46.4 mg/kg/day
i.I. (B). 5-ASA was used in doses of 2 x 21.5 mg/kg/day p.o. (A) and
21.5 mg/kg/day i.I. (B). Each bar represents the mean (___SEM) of ten
rats/group. p < 0.05 vs. vehicle-treated TN BS-sensitized animals.
resulted in a 60% or 50% reduction (Fig. 7B).
Histological examination of drug-treated groups
showed no or only few and small inflamed segments
in all animals tested.
Discussion
Since IBD-like diseases do not occur naturally in
animals, different types of exogenous irritants were
used to induce inflammatory reactions of the gut.
Though the importance of the immune system in
the course of human IBDs is still unknown, an
immunological involvement cannot be exclud-
ed. 1-3’s-8 Therefore, an immunological type of
irritant seems to be a suitable tool for inducing an
IBD-like intestinal inflammation in rats.
DNCB and TNCB (di- or tri-nitrochlorobenzene)
are very potent haptens. When bound to tissue
protein they have been shown to elicit cell-mediated
immune responses.
9-1s Animals can be sensitized by
an application of DNCB or TNCB to their skin,
which induces a reproducible and prolonged
delayed type of hypersensitivity. In contrast to
DNCB and TNCB, TNBS, the hapten used in this
investigation, is water-soluble;
is this property is
required for local administration by a catheter.
TNBS by itself did not induce any immunological
reaction, as mentioned in the results. However,
when TNBS was bound to OA as a carrier and
reinforced by Freund’s adjuvant, an immunological
response similar to that after DNCB or TNCB was
obtained. The specificity of the TNBS-induced
sensitization was investigated by skin injections of
low and inactive doses of the hapten, with or
without binding to OA, or OA alone. A clear
delayed type of hypersensitivity was observed only
against the hapten TNBS. It was reproducible for
more than 9 months as examined by monthly skin
tests.
Local treatment of the intestine with TNBS
following immunization was shown to induce an
inflammation of the rat gut very similar to human
Crohn’s disease. In particular, the histologically
observed infiltration of lymphocytes and histiocytes
is exactly as described for the human disease.
18 In
addition, the induced transmural inflammatory
reaction involving all layers of the intestinal wall,
including the mesenteric lymph nodes, the
occurrence of granulomas with multinucleated
giant cells, and the fact that all goblet cells remain
intact
1 are features of the animal model that show
similarity to Crohn’s disease.
The macroscopic description of the inflammatory
reaction of the distal small intestine treated by
multiple local TNBS administration includes
intensity and redness or haemorrhage as one of the
main parameters of inflammation as outlined in the
methods. This scoring system was chosen as it is
easy to determine, robust and is only minimally
subject to observer bias. Ulceration was never seen
after low dose TNBS treatment but can be induced
by higher doses (personal observation).
In animals not previously sensitized to TNBS no
transmural chronic inflammation could be induced
by intrajejunal administration of TNBS, although
TNBS was used in concentrations up to 0.5%.
These results support the hypothesis of immune
involvement in the aetiology of inflammatory bowel
diseases, ’5’9 in which conversion of lymphocyte
reactivity is discussed as a possible pathogenic
parameter.
One main difference from Crohn’s disease is the
non-occurrence of a discontinuous inflammation
characterized by the typically observed pattern of
remission and relapse, and the typical mixture of
chronic and acute inflammation. However, the
prolonged reactivity against TNBS in the present
investigation may provide a chance to mimic the
course of the human disease by discontinuous
intraluminal application of the hapten in sensitized
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animals and variation of the concentration of the
hapten.
The efficacy of 5-ASA and sulphasalazine in this
model is another aspect that emphasizes the
similarity of the model to the human disease. Both
drugs represent the most important clinically used
drugs for IBD, and in this investigation they were
used at a dose which is effective in human
treatments. The mentioned differences between i.1.
and p.o. administration on LTB4 and enteritis score
were difficult to rationalize. Reduction of LTB4 was
more pronounced by oral than intraluminal drug
administration, whereas reduction of the enteritis
score was more pronounced by intraluminal drug
administration. The reason for these differences is
not yet clear. Future investigations and dose-
dependent studies are needed, especially as the
overall efficacy of sulphasalazine in this model is
higher than expected considering that only colonic
bacteria can split the molecule into sulphapyridine
and the active 5-ASA moiety.
The inflammation mediator LTB4,1%21 often
found to be increased in patients with inflammatory
bowel diseases,22’23 was additionally determined in
this model. Levels of LTB4 in TNBS-treated
animals were significantly increased as compared to
controls. Another characteristic of the human
disease is therefore demonstrated in this animal
model. Again, the relevance of this parameter for
the aetiology or the course of the disease remains
unclear as it is not known whether it is a primary
or secondary event in the process of the disease. In
addition, the determination of lipoxygenase product
formation of the intestine should be tested by direct
extraction of the inflamed tissue especially by
HPLC-techniques in order to avoid artificial errors.
Due to the multifactorial origin of the human
disease the determination of other mediators and
cytokines in this model would be of great interest
and helpful for further characterization of the
model. From the histological findings the increase
of LTB4-1ike material determined in this model did
not seem to be caused by neutrophils; only
macrophages or mast cells will be assumed as the
sources for leukotriene production.
In contrast to other immunologically-induced
chronic inflammations of the gut as animal models
of IBD,4’%14 chronicity of the inflammatory reaction
in this model was induced by multiple instead of
one
4 or few10’13’14 local administrations of the
immunogen. Another difference is a 3 week instead
of 3 day1’13’14 time schedule for the local challenge
procedure. This proposed continuous and weak
stimulation of the immune system by one specific
immunogen seems to be an opportunity to mimic
the human disease more closely and the model has
more features in common with human IBDs than
non-immunological and acute models.24
In conclusion, the presented animal model of
IBD is rather complex and time-consuming due to
the immunization procedure and the sustained local
treatment. However, this challenge relates to the
characteristics of a chronic disease and provides a
reproducible model of chronic and immunologi-
cally-induced inflammatory bowel disease.
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